| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Serge Halim. [Management of type 2 diabetes: new or previous agents, how to choose?]. Presse medicale (Paris, France : 1983). vol 42. issue 5. 2013-08-02. PMID:23643613. |
the use of glp-1 analogues is often delayed today and put wrongly in balance with the transition to insulin, a use already delayed in france and insufficient. |
2013-08-02 |
2023-08-12 |
Not clear |
| Noboru Furukawa, Eiichi Arak. [Type 2 diabetes and impaired glucose tolerance]. Nihon rinsho. Japanese journal of clinical medicine. vol 71. issue 2. 2013-07-30. PMID:23631205. |
in drug therapy of such patients, the drugs to improve insulin resistance, such as biguanides, thiazolidine derivatives, dpp-4 inhibitors and glp-1 analogues should be selected. |
2013-07-30 |
2023-08-12 |
human |
| Caio E G Reis, Daniela N Ribeiro, Neuza M B Costa, Josefina Bressan, Rita C G Alfenas, Richard D Matte. Acute and second-meal effects of peanuts on glycaemic response and appetite in obese women with high type 2 diabetes risk: a randomised cross-over clinical trial. The British journal of nutrition. vol 109. issue 11. 2013-07-29. PMID:23122211. |
postprandial concentrations (0-490 min) of glucose, insulin, nefa, glucagon-like peptide-1 (glp-1), peptide yy (pyy), cholecystokinin (cck), appetitive sensations and food intake were assessed after breakfast treatments and a standard lunch. |
2013-07-29 |
2023-08-12 |
Not clear |
| Hiroyuki Koshiyam. Further possible mechanisms of dipeptidyl peptidase-4 inhibitors to decrease blood glucose in subjects with type 2 diabetes. Japanese clinical medicine. vol 2. 2013-07-25. PMID:23885193. |
i present here several possible mechanisms of dpp-4 inhibitors to reduce blood glucose in type 2 diabetes; first, to inhibit glucagon secretion, second, to stimulate glucose-dependent insulinotropic peptide (gip) secretion, which may regain its action to stimulate insulin secretion when hyperglycemia has been improved, third, to recover the response to sulfonylureas by restoring pancreatic atp levels, fourth, to stimulate glucagon-like peptide 1 (glp-1 ) secretion directly from the intestine, and finally to inhibit the action of dpp-4 as an adipokine. |
2013-07-25 |
2023-08-12 |
human |
| Nirav Dhanesha, Amit Joharapurkar, Gaurang Shah, Vipin Dhote, Samadhan Kshirsagar, Rajesh Bahekar, Mukul Jai. Exendin-4 ameliorates diabetic symptoms through activation of glucokinase. Journal of diabetes. vol 4. issue 4. 2013-07-16. PMID:22356440. |
glucagon-like peptide-1 (glp-1) and its stable analogue exendin-4 maintain glucose homeostasis by modulating insulin secretion from pancreatic β-cells and controlling hepatic glucose output. |
2013-07-16 |
2023-08-12 |
mouse |
| Vikas K Bhat, Barry D Kerr, Peter R Flatt, Victor A Gaul. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties. Biochemical pharmacology. vol 85. issue 11. 2013-07-16. PMID:23518155. |
da(2)gip-oxm exerts positive beneficial actions on glucose homeostasis, beta-cell insulin secretion and body weight, mediated through gip, glucagon and glp-1 receptors. |
2013-07-16 |
2023-08-12 |
mouse |
| Guochun Luo, Xiangchen Kong, Lina Lu, Xiaohui Xu, Hui Wang, Xiaosong M. Glucagon-like peptide 1 potentiates glucotoxicity-diminished insulin secretion via stimulation of cAMP-PKA signaling in INS-1E cells and mouse islets. The international journal of biochemistry & cell biology. vol 45. issue 2. 2013-07-05. PMID:23220045. |
glucagon-like peptide-1 (glp-1)-enhanced insulin secretion is mainly mediated by camp-pka and camp-epac2 signaling pathways at physiological glucose concentrations. |
2013-07-05 |
2023-08-12 |
mouse |
| Guochun Luo, Xiangchen Kong, Lina Lu, Xiaohui Xu, Hui Wang, Xiaosong M. Glucagon-like peptide 1 potentiates glucotoxicity-diminished insulin secretion via stimulation of cAMP-PKA signaling in INS-1E cells and mouse islets. The international journal of biochemistry & cell biology. vol 45. issue 2. 2013-07-05. PMID:23220045. |
in the present study, we examined the effects of glp-1 on glucotoxicity-diminished insulin secretion and explored the roles of these two camp-linked pathways in mediating the effects of glp-1 under glucotoxic conditions. |
2013-07-05 |
2023-08-12 |
mouse |
| Guochun Luo, Xiangchen Kong, Lina Lu, Xiaohui Xu, Hui Wang, Xiaosong M. Glucagon-like peptide 1 potentiates glucotoxicity-diminished insulin secretion via stimulation of cAMP-PKA signaling in INS-1E cells and mouse islets. The international journal of biochemistry & cell biology. vol 45. issue 2. 2013-07-05. PMID:23220045. |
addition of 10nm glp-1 significantly increased glucose-stimulated insulin secretion. |
2013-07-05 |
2023-08-12 |
mouse |
| Guochun Luo, Xiangchen Kong, Lina Lu, Xiaohui Xu, Hui Wang, Xiaosong M. Glucagon-like peptide 1 potentiates glucotoxicity-diminished insulin secretion via stimulation of cAMP-PKA signaling in INS-1E cells and mouse islets. The international journal of biochemistry & cell biology. vol 45. issue 2. 2013-07-05. PMID:23220045. |
moreover, glp-1 did not increase further insulin secretion in the presence of the pka agonist 6-bnz-camp-am. |
2013-07-05 |
2023-08-12 |
mouse |
| Guochun Luo, Xiangchen Kong, Lina Lu, Xiaohui Xu, Hui Wang, Xiaosong M. Glucagon-like peptide 1 potentiates glucotoxicity-diminished insulin secretion via stimulation of cAMP-PKA signaling in INS-1E cells and mouse islets. The international journal of biochemistry & cell biology. vol 45. issue 2. 2013-07-05. PMID:23220045. |
taken together, our results suggest that glp-1 potentiates glucotoxicity-diminished insulin secretion mainly through camp-pka signaling pathway. |
2013-07-05 |
2023-08-12 |
mouse |
| Andreas B Petersen, Mikkel Christense. Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus. Diabetes, metabolic syndrome and obesity : targets and therapy. vol 6. 2013-07-05. PMID:23825925. |
lixisenatide activates the glp-1 receptor and thereby exercises the range of physiological effects generated by glp-1, which consist of increased insulin secretion, inhibition of glucagon secretion, and decreased gastrointestinal motility alongside the promotion of satiety. |
2013-07-05 |
2023-08-12 |
Not clear |
| J J Holst, T Vilsbøl. Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes, obesity & metabolism. vol 15. issue 1. 2013-07-02. PMID:22646532. |
combining glp-1 receptor agonists with insulin: therapeutic rationales and clinical findings. |
2013-07-02 |
2023-08-12 |
Not clear |
| A R Meloni, M B DeYoung, C Lowe, D G Parke. GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. Diabetes, obesity & metabolism. vol 15. issue 1. 2013-07-02. PMID:22776039. |
glp-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. |
2013-07-02 |
2023-08-12 |
rat |
| K Færch, K Pilgaard, F K Knop, T Hansen, O Pedersen, T Jørgensen, J J Hols. Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the TCF7L2 rs7903146 risk T allele. Diabetes, obesity & metabolism. vol 15. issue 1. 2013-07-02. PMID:22862926. |
we characterised 62 non-diabetic, middle-aged, caucasians with and without the t risk allele of rs7903146 in transcription factor 7-like 2 (tcf7l2) with regard to secretion of insulin, glucagon, glucose-dependent insulinotropic polypeptide (gip), glucagon-like peptide-1 (glp-1) as well as insulin sensitivity and endogenous glucose production. |
2013-07-02 |
2023-08-12 |
human |
| K Færch, K Pilgaard, F K Knop, T Hansen, O Pedersen, T Jørgensen, J J Hols. Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the TCF7L2 rs7903146 risk T allele. Diabetes, obesity & metabolism. vol 15. issue 1. 2013-07-02. PMID:22862926. |
we found no significant differences in endogenous glucose production, hepatic insulin sensitivity or fasting concentrations of glucose, insulin, glucagon and glp-1 between the groups. |
2013-07-02 |
2023-08-12 |
human |
| Zachary T Bloomgarden, Lawrence Blonde, Alan J Garber, Carol H Wysha. Current issues in GLP-1 receptor agonist therapy for type 2 diabetes. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. vol 18 Suppl 3. 2013-06-27. PMID:23315305. |
topics that may be of particular interest to clinicians who treat t2dm patients include relative glycemic control efficacy of glp-1 ras, use of glp-1 ras across t2dm progression and in combination with insulin, recent data regarding glp-1 ra safety, nonglycemic actions of glp-1 ras, including weight effects, and impact of glp-1 ras on patient quality of life and treatment satisfaction. |
2013-06-27 |
2023-08-12 |
Not clear |
| C Benedict, J L Barclay, V Ott, H Oster, M Hallschmi. Acute sleep deprivation delays the glucagon-like peptide 1 peak response to breakfast in healthy men. Nutrition & diabetes. vol 3. 2013-06-27. PMID:23797385. |
the incretin hormone glucagon-like peptide 1 (glp-1) enhances postprandial insulin secretion and promotes satiety. |
2013-06-27 |
2023-08-12 |
Not clear |
| Sachin L Badole, Pranita P Bagul, Sagar P Mahamuni, Rekha D Khose, Anuja C Joshi, Ganesh B Jangam, Arvindkumar E Ghule, Chandrashekhar G Raut, Vijay M Khedkar, Evans C Coutinh. Oral L-glutamine increases active GLP-1 (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats. Chemico-biological interactions. vol 203. issue 2. 2013-06-26. PMID:23466488. |
glycosylated haemoglobin, lipid profile, plasma and colonic active (glp-1) (7-36) amide, mrna expression of proglucagon glp-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, glutathione s transferase) were measured after 8 week. |
2013-06-26 |
2023-08-12 |
rat |
| Sachin L Badole, Pranita P Bagul, Sagar P Mahamuni, Rekha D Khose, Anuja C Joshi, Ganesh B Jangam, Arvindkumar E Ghule, Chandrashekhar G Raut, Vijay M Khedkar, Evans C Coutinh. Oral L-glutamine increases active GLP-1 (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats. Chemico-biological interactions. vol 203. issue 2. 2013-06-26. PMID:23466488. |
plasma glucose, active glp-1 (7-36) amide concentration and insulin levels were measured after glucose loading. |
2013-06-26 |
2023-08-12 |
rat |